美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

Propanc Biopharma, Inc.

0.4400

-0.0457-9.41%

盘后：0.4305-0.0095-2.16%18:09 EDT

成交量：19.56万

成交额：8.82万

市值：278.57万

市盈率：-0.02

高：0.4899

开：0.4887

低：0.4250

收：0.4857

52周最高：47.50

52周最低：0.4250

股本：633.11万

流通股本：125.01万

量比：0.63

换手率：15.65%

股息：- -

股息率：- -

每股收益(TTM):-17.6157

每股收益(LYR):-371.2241

净资产收益率：-161.86%

总资产收益率：-70.14%

市净率：0.30

市盈率(LYR):0.00

数据加载中...

总览公司新闻资讯公告

Propanc Biopharma公布数据：Prp在胰腺癌模型中实现90%肿瘤生长抑制，与Revolution Medicines的Daraxonrasib形成鲜明对比

Propanc Biopharma计划开展1B期临床研究，拟纳入40-45名晚期实体瘤患者，临床试验申请预计数月内提交

Propanc Biopharma公布PRP新型临床前胰腺癌数据：肿瘤生长抑制率超90%，生存获益逾2.5倍

Propanc Biopharma宣布PRP在胰腺导管腺癌模型中展现超90%肿瘤生长抑制及显著生存获益的积极临床前与早期转化数据

Propanc Biopharma, Inc.将在澳大利亚提交CTA，启动针对30-40名晚期癌症患者的1B期研究

Propanc Biopharma公司计划开展两项II期研究，针对胰腺癌和卵巢癌各招募60名患者

Propanc Biopharma实施并股计划，以维系纳斯达克上市地位并推进增长战略

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hans/stock/PPCB/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PPCB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PPCB\",,,,,undefined,":{"symbol":"PPCB","market":"US","secType":"STK","nameCN":"Propanc Biopharma, Inc.","latestPrice":0.44,"timestamp":1791835200000,"preClose":0.4857,"halted":0,"volume":195642,"hourTrading":{"tag":"盘后","latestPrice":0.4305,"preClose":0.44,"latestTime":"18:09 EDT","volume":634,"amount":283.2089729,"timestamp":1791842974126,"change":-0.0095,"changeRate":-0.021591,"amplitude":0.078409},"delay":0,"changeRate":-0.09409100267654934,"floatShares":1250100,"shares":6331116,"eps":-17.61573,"marketStatus":"盘后交易","change":-0.0457,"latestTime":"10-12 18:14:41 EDT","open":0.4887,"high":0.4899,"low":0.425,"amount":88180.56437220001,"amplitude":0.133622,"askPrice":0.437,"askSize":526,"bidPrice":0.4,"bidSize":12183,"shortable":0,"etf":0,"ttmEps":-17.61573,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1791849600000},"marketStatusCode":4,"adr":0,"listingDate":1743998400000,"exchange":"NASDAQ","adjPreClose":0.4857,"preHourTrading":{"tag":"盘前","latestPrice":0.4745,"preClose":0.4857,"latestTime":"09:29 EDT","volume":22381,"amount":10564.52513957,"timestamp":1791811798004,"change":-0.0112,"changeRate":-0.02306,"amplitude":0.108915},"postHourTrading":{"tag":"盘后","latestPrice":0.4305,"preClose":0.44,"latestTime":"18:09 EDT","volume":634,"amount":283.2089729,"timestamp":1791842974126,"change":-0.0095,"changeRate":-0.021591,"amplitude":0.078409},"volumeRatio":0.629567},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PPCB\",,,,,undefined,":{"symbol":"PPCB","floatShares":1250100,"roa":"-70.14%","roe":"-161.86%","lyrEps":-371.224075,"volumeRatio":0.629567,"shares":6331116,"dividePrice":0,"high":0.4899,"amplitude":0.133622,"preClose":0.4857,"low":0.425,"week52Low":0.425,"pbRate":"0.30","week52High":47.5,"institutionHeld":0,"latestPrice":0.44,"committee":0.917224,"eps":-17.61573,"divideRate":0,"volume":195642,"delay":0,"ttmEps":-17.61573,"open":0.4887,"prevYearClose":13.415,"prevWeekClose":0.4857,"prevMonthClose":0.494,"prevQuarterClose":0.494,"fiveDayClose":0.5,"twentyDayClose":0.85,"sixtyDayClose":1.49},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PPCB\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-05-18","symbol":"PPCB","defaultRemindTime":1779111000000,"type":"split","dateTimestamp":1779076800000,"forFactor":25,"toFactor":1,"ratio":25},{"market":"US","date":"2025-01-29","symbol":"PPCB","defaultRemindTime":1738161000000,"type":"split","dateTimestamp":1738126800000,"forFactor":60000,"toFactor":1,"ratio":60000},{"market":"US","date":"2023-05-23","symbol":"PPCB","defaultRemindTime":1684848600000,"type":"split","dateTimestamp":1684814400000,"forFactor":1000,"toFactor":1,"ratio":1000},{"market":"US","date":"2020-11-19","symbol":"PPCB","defaultRemindTime":1605796200000,"type":"split","dateTimestamp":1605762000000,"forFactor":1000,"toFactor":1,"ratio":1000},{"market":"US","date":"2019-06-24","symbol":"PPCB","type":"split","dateTimestamp":1561348800000,"forFactor":500,"toFactor":1,"ratio":500}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PPCB\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PPCB\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PPCB\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PPCB","date":"2026-10-09","current":-0.024978,"percent":0.395189,"low":-1.336323,"twenty":-0.240182,"median":-0.12657,"eighty":-0.043866,"high":-0.023125,"avg":-0.177741,"sd":0.185229,"marketCap":2981955},"quantilePoints":[{"date":"2025-04-04","current":-0.050633,"twenty":-0.050633,"median":-0.050633,"eighty":-0.050633,"marketCap":84546},{"date":"2025-04-07","current":-0.048332,"twenty":-0.050633,"median":-0.050633,"eighty":-0.049713,"marketCap":80703},{"date":"2025-08-22","current":-0.938461,"twenty":-0.969897,"median":-0.655598,"eighty":-0.050633,"marketCap":51812834},{"date":"2025-08-29","current":-0.721182,"twenty":-0.884372,"median":-0.710781,"eighty":-0.050633,"marketCap":39816759},{"date":"2025-09-05","current":-0.457673,"twenty":-0.820575,"median":-0.688821,"eighty":-0.213449,"marketCap":25268328},{"date":"2025-09-12","current":-0.457673,"twenty":-0.778969,"median":-0.631034,"eighty":-0.41283,"marketCap":25268328},{"date":"2025-09-19","current":-0.506214,"twenty":-0.755854,"median":-0.517772,"eighty":-0.439644,"marketCap":27948302},{"date":"2025-09-26","current":-0.418378,"twenty":-0.712861,"median":-0.510837,"eighty":-0.435021,"marketCap":23098825},{"date":"2025-10-03","current":-0.399917,"twenty":-0.699454,"median":-0.498124,"eighty":-0.407301,"marketCap":23564414},{"date":"2025-10-10","current":-0.408611,"twenty":-0.69067,"median":-0.457673,"eighty":-0.403395,"marketCap":24076684},{"date":"2025-10-17","current":-0.343407,"twenty":-0.669984,"median":-0.449583,"eighty":-0.385572,"marketCap":20234660},{"date":"2025-10-24","current":-0.321672,"twenty":-0.645772,"median":-0.432247,"eighty":-0.369488,"marketCap":18953985},{"date":"2025-10-31","current":-0.269509,"twenty":-0.610693,"median":-0.4245,"eighty":-0.343407,"marketCap":15880366},{"date":"2025-11-07","current":-0.241906,"twenty":-0.556142,"median":-0.418378,"eighty":-0.313847,"marketCap":14253909},{"date":"2025-11-14","current":-0.169965,"twenty":-0.518234,"median":-0.404264,"eighty":-0.269509,"marketCap":10014876},{"date":"2025-11-21","current":-0.174454,"twenty":-0.514536,"median":-0.397743,"eighty":-0.234995,"marketCap":11061584},{"date":"2025-11-28","current":-0.188344,"twenty":-0.512687,"median":-0.384703,"eighty":-0.189884,"marketCap":11942288},{"date":"2025-12-05","current":-0.173885,"twenty":-0.509912,"median":-0.372748,"eighty":-0.182127,"marketCap":11025501},{"date":"2025-12-12","current":-0.170028,"twenty":-0.504827,"median":-0.356448,"eighty":-0.174606,"marketCap":10780935},{"date":"2025-12-19","current":-0.151754,"twenty":-0.498818,"median":-0.343407,"eighty":-0.171335,"marketCap":9622255},{"date":"2025-12-26","current":-0.139108,"twenty":-0.496968,"median":-0.326019,"eighty":-0.170682,"marketCap":8820401},{"date":"2026-01-02","current":-0.113099,"twenty":-0.476627,"median":-0.315152,"eighty":-0.168873,"marketCap":7171266},{"date":"2026-01-09","current":-0.101254,"twenty":-0.460447,"median":-0.284723,"eighty":-0.163023,"marketCap":6420182},{"date":"2026-01-16","current":-0.074044,"twenty":-0.457673,"median":-0.262988,"eighty":-0.151375,"marketCap":4694858},{"date":"2026-01-23","current":-0.056065,"twenty":-0.453513,"median":-0.243754,"eighty":-0.138341,"marketCap":3554888},{"date":"2026-01-30","current":-0.058573,"twenty":-0.449352,"median":-0.223866,"eighty":-0.121547,"marketCap":3713923},{"date":"2026-02-06","current":-0.042554,"twenty":-0.442879,"median":-0.192195,"eighty":-0.107345,"marketCap":2698240},{"date":"2026-02-13","current":-0.048688,"twenty":-0.435021,"median":-0.182701,"eighty":-0.093848,"marketCap":3087140},{"date":"2026-02-20","current":-0.048657,"twenty":-0.431486,"median":-0.176899,"eighty":-0.077306,"marketCap":3214676},{"date":"2026-02-27","current":-0.046857,"twenty":-0.428606,"median":-0.174834,"eighty":-0.060466,"marketCap":3095731},{"date":"2026-03-06","current":-0.040376,"twenty":-0.424799,"median":-0.173681,"eighty":-0.05647,"marketCap":2667530},{"date":"2026-03-13","current":-0.029045,"twenty":-0.422077,"median":-0.17085,"eighty":-0.050499,"marketCap":1918972},{"date":"2026-03-20","current":-0.028085,"twenty":-0.419765,"median":-0.170682,"eighty":-0.048484,"marketCap":1855535},{"date":"2026-03-27","current":-0.034166,"twenty":-0.417079,"median":-0.169454,"eighty":-0.047319,"marketCap":2257270},{"date":"2026-04-02","current":-0.035336,"twenty":-0.413827,"median":-0.167383,"eighty":-0.04606,"marketCap":2334602},{"date":"2026-04-10","current":-0.031762,"twenty":-0.406872,"median":-0.16427,"eighty":-0.043866,"marketCap":2098425},{"date":"2026-04-17","current":-0.033628,"twenty":-0.399911,"median":-0.155654,"eighty":-0.041322,"marketCap":2221738},{"date":"2026-04-24","current":-0.036697,"twenty":-0.399457,"median":-0.149858,"eighty":-0.040438,"marketCap":2424475},{"date":"2026-05-01","current":-0.032141,"twenty":-0.39557,"median":-0.138149,"eighty":-0.039889,"marketCap":2123505},{"date":"2026-05-08","current":-0.029421,"twenty":-0.386441,"median":-0.123469,"eighty":-0.037064,"marketCap":1943760},{"date":"2026-05-15","current":-0.023125,"twenty":-0.382964,"median":-0.117367,"eighty":-0.035899,"marketCap":1527837},{"date":"2026-05-22","current":-0.078772,"twenty":-0.376009,"median":-0.107725,"eighty":-0.036443,"marketCap":1446323},{"date":"2026-05-29","current":-0.077406,"twenty":-0.376009,"median":-0.101254,"eighty":-0.036697,"marketCap":1421242},{"date":"2026-06-05","current":-0.075584,"twenty":-0.369488,"median":-0.094421,"eighty":-0.037013,"marketCap":1387801},{"date":"2026-06-12","current":-0.110645,"twenty":-0.369488,"median":-0.091369,"eighty":-0.037013,"marketCap":2031540},{"date":"2026-06-18","current":-0.077861,"twenty":-0.359056,"median":-0.091369,"eighty":-0.037215,"marketCap":1429602},{"date":"2026-06-26","current":-0.068755,"twenty":-0.347754,"median":-0.088611,"eighty":-0.037494,"marketCap":1262397},{"date":"2026-07-02","current":-0.178687,"twenty":-0.344276,"median":-0.088611,"eighty":-0.038576,"marketCap":3280854},{"date":"2026-07-10","current":-0.220877,"twenty":-0.343407,"median":-0.091369,"eighty":-0.03962,"marketCap":4055500},{"date":"2026-07-17","current":-0.1973,"twenty":-0.335582,"median":-0.096459,"eighty":-0.039946,"marketCap":3622609},{"date":"2026-07-24","current":-0.179928,"twenty":-0.32515,"median":-0.101254,"eighty":-0.040156,"marketCap":3303637},{"date":"2026-07-31","current":-0.129051,"twenty":-0.321672,"median":-0.106776,"eighty":-0.040305,"marketCap":2369505},{"date":"2026-08-07","current":-0.16876,"twenty":-0.316456,"median":-0.111872,"eighty":-0.040388,"marketCap":3098584},{"date":"2026-08-14","current":-0.151387,"twenty":-0.306023,"median":-0.120497,"eighty":-0.04047,"marketCap":2779612},{"date":"2026-08-21","current":-0.136497,"twenty":-0.295156,"median":-0.123158,"eighty":-0.040781,"marketCap":2506208},{"date":"2026-08-28","current":-0.276716,"twenty":-0.28152,"median":-0.125329,"eighty":-0.041146,"marketCap":5080767},{"date":"2026-09-04","current":-0.12657,"twenty":-0.273833,"median":-0.12719,"eighty":-0.041245,"marketCap":2323938},{"date":"2026-09-11","current":-0.11699,"twenty":-0.269509,"median":-0.12657,"eighty":-0.041322,"marketCap":2148048},{"date":"2026-09-18","current":-0.078175,"twenty":-0.266901,"median":-0.125329,"eighty":-0.041661,"marketCap":1435373},{"date":"2026-09-25","current":-0.074676,"twenty":-0.254295,"median":-0.123158,"eighty":-0.042494,"marketCap":1371123},{"date":"2026-10-02","current":-0.168157,"twenty":-0.244862,"median":-0.125329,"eighty":-0.042786,"marketCap":3171889},{"date":"2026-10-09","current":-0.158087,"twenty":-0.240182,"median":-0.12657,"eighty":-0.043866,"marketCap":2981955}],"updateTime":1791843281704},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PPCB\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1165197599","title":"Propanc Biopharma公布数据：Prp在胰腺癌模型中实现90%肿瘤生长抑制，与Revolution Medicines的Daraxonrasib形成鲜明对比","url":"https://stock-news.laohu8.com/highlight/detail?id=1165197599","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165197599?lang=zh_cn&edition=fundamental","pubTime":"2026-10-07 20:31","pubTimestamp":1791376271,"startTime":"0","endTime":"0","summary":"Propanc Biopharma公布数据：Prp在胰腺癌模型中实现90%肿瘤生长抑制，与Revolution Medicines的Daraxonrasib形成鲜明对比","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PPCB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145921717","title":"Propanc Biopharma计划开展1B期临床研究，拟纳入40-45名晚期实体瘤患者，临床试验申请预计数月内提交","url":"https://stock-news.laohu8.com/highlight/detail?id=1145921717","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145921717?lang=zh_cn&edition=fundamental","pubTime":"2026-08-27 20:32","pubTimestamp":1787833930,"startTime":"0","endTime":"0","summary":"Propanc Biopharma公司宣布，其计划推进一项1B期临床研究，该研究拟招募40至45名患有晚期实体瘤的患者。据公司透露，相关临床试验申请预计将在未来数月内正式递交。通过这项研究，Propanc Biopharma旨在进一步评估其候选药物的安全性和初步疗效，为后续更大规模的临床开发奠定基础。随着申请日期的临近，业界将密切关注监管机构的反馈以及该研究的后续进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PPCB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188382612","title":"Propanc Biopharma公布PRP新型临床前胰腺癌数据：肿瘤生长抑制率超90%，生存获益逾2.5倍","url":"https://stock-news.laohu8.com/highlight/detail?id=1188382612","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188382612?lang=zh_cn&edition=fundamental","pubTime":"2026-08-27 20:31","pubTimestamp":1787833890,"startTime":"0","endTime":"0","summary":"Propanc Biopharma, Inc. 近日揭晓了一项针对其候选药物PRP的临床前研究新成果，数据令人瞩目。研究显示，该药物在胰腺癌模型中展现出强劲的抗肿瘤活性，肿瘤生长抑制率突破90%大关，同时将实验对象的生存期延长了2.5倍以上。这一发现为胰腺癌这一难治性肿瘤的治疗策略带来了新的曙光。Propanc Biopharma表示，团队正加速评估这些数据，并规划后续的研发路径，以期尽快将这一潜在疗法惠及全球患者。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PPCB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159793711","title":"Propanc Biopharma宣布PRP在胰腺导管腺癌模型中展现超90%肿瘤生长抑制及显著生存获益的积极临床前与早期转化数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1159793711","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1159793711?lang=zh_cn&edition=fundamental","pubTime":"2026-08-06 20:37","pubTimestamp":1786019874,"startTime":"0","endTime":"0","summary":"Propanc Biopharma, Inc. 近日公布了其核心候选药物PRP的积极临床前和早期转化研究结果。在胰腺导管腺癌（PDAC）模型中，PRP显示出超过90%的肿瘤生长抑制率，并显著延长了实验对象的生存期。这一里程碑式的数据，为后续的临床开发奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PPCB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136433126","title":"Propanc Biopharma, Inc.将在澳大利亚提交CTA，启动针对30-40名晚期癌症患者的1B期研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1136433126","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136433126?lang=zh_cn&edition=fundamental","pubTime":"2026-05-20 20:46","pubTimestamp":1779281202,"startTime":"0","endTime":"0","summary":"Propanc Biopharma, Inc. 计划在澳大利亚提交临床试验申请，旨在启动一项涉及30至40名晚期癌症患者的1B期研究。这一举措标志着该公司在推进其新型癌症治疗方案的临床开发道路上迈出了关键一步。在澳大利亚提交CTA的决定，反映了公司利用该国高效监管框架和强大临床研究生态系统的战略考量。成功完成此阶段研究，有望为Propanc Biopharma, Inc.的核心产品管线带来重要的价值提升，并为其针对难治性癌症的开发策略提供关键支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PPCB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186690041","title":"Propanc Biopharma公司计划开展两项II期研究，针对胰腺癌和卵巢癌各招募60名患者","url":"https://stock-news.laohu8.com/highlight/detail?id=1186690041","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186690041?lang=zh_cn&edition=fundamental","pubTime":"2026-05-20 20:46","pubTimestamp":1779281199,"startTime":"0","endTime":"0","summary":"Propanc Biopharma公司宣布，将启动两项独立的II期临床研究，分别针对胰腺癌和卵巢癌患者。据悉，每项研究计划招募60名参与者，以评估其候选疗法的安全性与有效性。这一举措标志着该公司在推进其肿瘤治疗管线方面迈出了重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PPCB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158942593","title":"Propanc Biopharma实施并股计划，以维系纳斯达克上市地位并推进增长战略","url":"https://stock-news.laohu8.com/highlight/detail?id=1158942593","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1158942593?lang=zh_cn&edition=fundamental","pubTime":"2026-05-14 10:00","pubTimestamp":1778724015,"startTime":"0","endTime":"0","summary":"Propanc Biopharma公司已正式执行反向股票分割（并股）方案。此举旨在满足纳斯达克资本市场持续上市的最低股价要求，从而稳固其上市地位。同时，公司期望这一资本结构调整能为其既定的长期业务增长与拓展计划提供更坚实的基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PPCB"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":7,"code":"91000000","status":"200"}]}}